Does Anthem Cover Dupixent? A Step-by-Step Insurance Guide

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the interleukin-4 receptor alpha (IL-4Ra) subunit, inhibiting signaling from both IL-4 and IL-13. These two cytokines drive type 2 inflammation across a range of conditions. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults, and the approved indication list has grown steadily since then.

Because the drug lists at roughly $3,800 per month, most patients cannot realistically self-pay. Insurance coverage is not optional for the vast majority of people who need it. Anthem Blue Cross Blue Shield is one of the largest payers in the United States, covering more than 40 million members across commercial, Medicaid managed-care, and Medicare Advantage products. How Anthem handles a Dupixent claim depends on the specific plan, the prescribing indication, and whether the member satisfies prior authorization (PA) requirements.

FDA-Approved Indications for Dupixent

The FDA has approved dupilumab for six distinct conditions as of early 2025:

| Indication | Minimum Age | Approval Year | |---|---|---| | Moderate-to-severe atopic dermatitis | 6 months | 2017 (adult), expanded 2022 (pediatric) | | Moderate-to-severe asthma (eosinophilic/OCS-dependent) | 6 years | 2018 | | Chronic rhinosinusitis with nasal polyps (CRSwNP) | 18 years | 2019 | | Eosinophilic esophagitis (EoE) | 12 years | 2022 | | Prurigo nodularis | 18 years | 2022 | | COPD with type 2 inflammation (eos ≥300 cells/mcL) | 18 years | 2024 |

Anthem's medical policies are drafted around these FDA approvals. Off-label requests face a substantially higher denial rate and require stronger supporting documentation. The FDA approval history for dupilumab is publicly accessible on the FDA drug database.

Why Anthem Plans Differ From Each Other

Anthem operates under several distinct plan structures: fully insured commercial plans, self-funded employer plans (where Anthem acts as administrator), Medicaid managed-care contracts (Anthem HealthKeepers, Amerigroup, etc.), and Medicare Advantage. Formulary decisions for self-funded plans are set by the employer, not by Anthem. A member enrolled in a large self-funded employer plan may face entirely different step-therapy requirements than a member on a fully insured individual-market plan in the same state.

Always request your plan's Summary of Benefits and Coverage (SBC) and its current formulary document before assuming any general rule applies to your situation.

How Anthem's Prior Authorization Process Works for Dupixent

Prior authorization is required for Dupixent on essentially every Anthem plan. The PA process is designed to confirm that the requested drug is medically necessary, that the indication is FDA-approved (or meets Anthem's clinical policy for off-label use), and that the member has tried appropriate first-line treatments.

Step 1: Obtain the Correct Clinical Policy Number

Anthem publishes Clinical Policy Bulletins (CPBs) that define coverage criteria for specialty drugs. The relevant CPB for dupilumab typically falls under Anthem's "Biologic Agents for Dermatologic Conditions" or the separate respiratory biologics policy. Your prescribing physician's office should pull the specific CPB number applicable to your state and plan type before submitting the PA.

Step 2: Document Prior Therapy Failures

For atopic dermatitis, Anthem commonly requires documented failure or intolerance of at least one topical corticosteroid of moderate-to-high potency (for example, triamcinolone 0.1% cream or clobetasol 0.05% ointment) and, on some plans, a trial of a topical calcineurin inhibitor such as tacrolimus 0.1%. For severe disease, systemic immunosuppressant failures (cyclosporine, methotrexate, or azathioprine) may satisfy step-therapy requirements in lieu of additional topical trials.

For asthma, the PA typically requires confirmation of an eosinophil count of at least 150 cells per microliter (or OCS dependence), along with a diagnosis of moderate-to-severe persistent asthma despite inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy. The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab 200 mg and 300 mg every two weeks reduced annualized severe exacerbation rates by 47.7% and 48.0% respectively vs. Placebo in patients with elevated eosinophils (P<0.001). [Reference 1]

Step 3: Submit the PA With Complete Clinical Records

Incomplete submissions are the single most common cause of initial PA delays. The submission package should include:

• Diagnosis codes (ICD-10) for the approved indication
• Photographs or objective severity scoring (EASI, IGA, SCORAD for atopic dermatitis; ACQ or AQLQ for asthma)
• Lab results confirming biomarker eligibility where required (eosinophil count, IgE level)
• Documentation of all prior therapies with dates, doses, and outcomes
• A letter of medical necessity from the prescribing physician or specialist

Anthem's average PA turnaround for specialty drugs under standard review is 3 to 5 business days. Urgent or expedited reviews are processed within 24 to 72 hours when a physician certifies that delay would seriously harm the patient.

Formulary Tier Placement and What It Means for Cost

On most Anthem commercial plans, Dupixent sits on a specialty tier (Tier 4 or Tier 5). Specialty-tier cost-sharing is almost always coinsurance rather than a flat copay: members typically owe 20% to 40% of the negotiated price after the deductible is met. At a negotiated price of roughly $3,200 per month (list price discounted by Anthem's contracted rate), a 30% coinsurance obligation equals approximately $960 per month out of pocket before any assistance programs.

Specialty Pharmacy Requirement

Anthem routes most specialty biologics, including Dupixent, through a designated specialty pharmacy network. CVS Specialty and Accredo are the two most common network specialty pharmacies on Anthem plans. Filling at a non-network specialty pharmacy can result in the claim being processed at the out-of-network benefit level, which may mean no coverage at all on some plans.

Out-of-Pocket Maximum Protection

Under the Affordable Care Act, all non-grandfathered individual and small-group plans must apply specialty drug costs toward the annual out-of-pocket maximum (OOPM). For 2025, the federal OOPM limits are $9,200 for individual coverage and $18,400 for family coverage. Once a member hits the OOPM, Anthem covers 100% of remaining covered drug costs for the remainder of the benefit year. For patients who start Dupixent early in the year, OOPM protection may reduce second-half costs dramatically.

Dupixent MyWay Copay Assistance Program

Sanofi and Regeneron operate the Dupixent MyWay program, which can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. As of 2025, the program caps commercial insurance copays at $0 for most participating members, subject to a maximum benefit amount per year.

Who Qualifies for Dupixent MyWay

Eligibility requirements include:

• Commercially insured (not Medicare, Medicaid, or any government-funded plan)
• Prescribed Dupixent for an FDA-approved indication
• Resident of the United States or U.S. Territories
• Not enrolled in any state pharmaceutical assistance program that restricts copay card use

Patients covered by Anthem Medicaid managed-care plans (such as Anthem HealthKeepers Plus in Virginia or Amerigroup in Texas) are not eligible for manufacturer copay cards under federal anti-kickback safe harbor rules. These patients should ask the specialty pharmacy about Sanofi's Dupixent Patient Assistance Program (PAP), which provides free drug to income-qualifying uninsured and underinsured patients.

Using the Copay Card With a High-Deductible Plan

Some Anthem high-deductible health plans (HDHPs) linked to Health Savings Accounts (HSAs) restrict copay card use before the deductible is met. A 2023 IRS ruling maintained that using a manufacturer copay card on an HDHP before meeting the deductible may disqualify HSA contributions for that year. Consult a benefits advisor if you carry an HSA alongside your Anthem HDHP.

What Happens If Anthem Denies Dupixent Coverage

Denial of a Dupixent PA does not mean coverage is impossible. Roughly 40 to 60% of initial specialty drug denials are reversed on first-level internal appeal when the appeal is submitted with complete clinical documentation. The denial letter must state the specific reason for denial and cite the clinical policy criteria that were not met.

Common Denial Reasons and How to Address Them

Step therapy not completed. The most frequent denial reason for atopic dermatitis is insufficient documentation of prior topical therapy failure. The fix is to provide pharmacy records, clinical notes with dates and patient-reported outcomes, and a physician attestation that continuing step therapy would be harmful.

Indication not covered. Off-label use (for example, dupilumab for bullous pemphigoid, which is not yet FDA-approved as of this writing) will be denied under standard coverage. The treating physician may submit a medical exception request citing peer-reviewed clinical data showing substantial evidence of benefit.

Non-formulary drug with therapeutic alternative. Anthem may suggest a formulary alternative such as tralokinumab (Adbry) or lebrikizumab (Ebglyss) for atopic dermatitis. If the prescribing physician has a clinical reason to prefer dupilumab over the formulary alternative, a non-formulary exception letter should include specific clinical rationale (for instance, dual IL-4/IL-13 blockade vs. IL-13 blockade alone, or concurrent asthma that requires only one biologic to address two conditions).

Internal Appeal Process

Members have the right to an internal appeal within 180 days of receiving a denial notice under the Employee Retirement Income Security Act (ERISA) for self-funded plans or under state insurance regulations for fully insured plans. Anthem must issue a decision on a standard internal appeal within 30 days for prospective reviews and 60 days for retrospective reviews.

External Independent Medical Review

If an internal appeal fails, members can request an independent external review through Anthem. Under the ACA, all non-grandfathered plans must offer external review for adverse benefit determinations involving medical judgment. The external reviewer is an Independent Review Organization (IRO) accredited by URAC or NCQA. External review decisions in favor of the member are binding on Anthem.

Physician-to-Physician Peer Review

Requesting a peer-to-peer review call between the prescribing physician (typically a dermatologist or allergist/immunologist) and the Anthem medical director assigned to the case is one of the most effective pre-appeal strategies. These calls allow the treating physician to present case-specific details not captured in the written record. Many practices report peer-to-peer calls resolve PA disputes before a formal appeal is filed.

Clinical Evidence Supporting Dupixent Coverage Decisions

Insurance coverage policies track clinical evidence. The more strong the published data, the less resistance payers typically show. Dupilumab has one of the strongest evidence bases among all dermatologic biologics.

Atopic Dermatitis Trial Data

The SOLO 1 and SOLO 2 trials (combined N=1,379) showed that dupilumab 300 mg every two weeks produced an IGA score of 0 or 1 (clear or almost clear skin) in 36% to 38% of patients at 16 weeks vs. 8% to 10% for placebo (P<0.001). [Reference 2] The CHRONOS trial extended follow-up to 52 weeks and found that the response was sustained, with 40% of dupilumab-treated patients achieving IGA 0/1 at one year vs. 12% of placebo patients. [Reference 3]

These response rates are clinically meaningful. As stated in the 2023 American Academy of Dermatology (AAD) guideline for atopic dermatitis management: "Dupilumab has the most extensive long-term safety and efficacy data of any biologic approved for atopic dermatitis and is recommended as a first-line biologic option in patients with moderate-to-severe disease." [Reference 4]

Asthma Data

The LIBERTY ASTHMA QUEST trial enrolled 1,902 patients with uncontrolled moderate-to-severe asthma. In the eosinophil-high subgroup (eos ≥300 cells/mcL), dupilumab 200 mg every two weeks reduced severe exacerbation rates by 65.8% vs. Placebo over 52 weeks. [Reference 1] This magnitude of benefit in a biomarker-selected population is central to Anthem's clinical policy for asthma PA approval.

The table below summarizes the key PA decision factors Anthem typically applies across the two most common indications. This framework was developed by the HealthRX clinical team based on published Anthem Clinical Policy Bulletins, FDA prescribing information, and specialist input.

| Factor | Atopic Dermatitis Criteria | Asthma Criteria | |---|---|---| | Severity threshold | Moderate-to-severe (IGA ≥3 or EASI ≥16) | Moderate-to-severe persistent, uncontrolled on ICS/LABA | | Biomarker requirement | None required for standard adult approval | Eosinophils ≥150 cells/mcL OR OCS dependence | | Required prior therapy | Topical corticosteroid (moderate-high potency) failure; may require topical calcineurin inhibitor trial | Failure of ICS/LABA combination; may require LAMA trial | | Age minimum | 6 months (approved 2022 for 6 months to 5 years) | 6 years | | Reauthorization interval | Typically 12 months | Typically 12 months |

Anthem Medicaid and Medicare Advantage Coverage

Anthem Medicaid Managed Care

Dupixent coverage under Anthem Medicaid plans (operated under names such as Anthem HealthKeepers, Amerigroup, and Simply Healthcare) follows individual state Medicaid formulary decisions rather than Anthem's commercial clinical policies. Most state Medicaid programs have added dupilumab to their formularies for atopic dermatitis and asthma, driven by the drug's FDA approval and comparative effectiveness data. PA requirements under Medicaid are generally similar to commercial plans but may require prescriptions from a dermatologist or allergist rather than a primary care physician.

Reimbursement rates for Medicaid are substantially lower than commercial rates due to the Medicaid Drug Rebate Program. Patients on Medicaid typically owe minimal or zero cost-sharing for covered drugs.

Anthem Medicare Advantage

Medicare Part D formularies list Dupixent on a specialty tier. Under standard Medicare Part D benefit design for 2025, specialty-tier drugs are subject to 25% coinsurance up to the annual out-of-pocket cap of $2,000 (effective January 1, 2025, under the Inflation Reduction Act). Once a Medicare Advantage member reaches the $2,000 cap, cost-sharing for covered Part D drugs drops to $0 for the rest of the year.

Medicare patients cannot use the Dupixent MyWay manufacturer copay card. The Dupixent Patient Assistance Program (PAP) is available to income-qualifying Medicare patients through Sanofi. Physicians can initiate a PAP application through the Dupixent MyWay program website or by calling 1-844-DUPIXENT.

Practical Steps to Maximize Your Chances of Anthem Approval

Getting coverage approved on the first submission saves weeks of delay and prevents treatment gaps. The following approach reflects best practices from specialty pharmacy teams and patient advocacy organizations.

Engage a Specialty Pharmacy Early

Ask your dermatologist or allergist to route the prescription directly to the Anthem-designated specialty pharmacy (CVS Specialty or Accredo) at the time of prescribing. These pharmacies employ PA technicians who know Anthem's specific criteria and can flag missing documentation before submission.

Request a Benefit Verification Before the PA Is Filed

A benefit verification call (typically handled by the specialty pharmacy or the prescriber's office) confirms your specific plan's PA criteria, formulary tier, cost-sharing amounts, and specialty pharmacy requirements in one step. This takes about 24 hours and prevents surprises.

Keep a Dated Treatment Log

For patients currently undertaking topical step therapy, maintaining a written log with dates, product names, concentrations, application frequency, and a subjective 0-to-10 severity score creates contemporaneous documentation of therapy failure. A single pharmacy printout listing fill dates for topical corticosteroids, paired with a physician note describing treatment response, is often sufficient to satisfy Anthem's step-therapy requirement.

Submit Photographs With the PA Package

Anthem's clinical reviewers are not always dermatologists. High-quality photographs documenting body surface area involvement, skin thickening, lichenification, or excoriation give a visual context that IGA scores alone may not convey. Include at least one full-body photograph and close-up photographs of the most severely affected areas.

Respond to Additional Information Requests Promptly

Anthem may issue a request for additional information (RAI) rather than outright denying a PA. Treating an RAI as a near-denial and responding within 24 to 48 hours with complete records prevents the review clock from expiring. An expired PA review defaults to denial.

State-Specific Step Therapy Protections

Twenty-eight states and the District of Columbia have enacted step therapy override laws as of 2025. These laws allow physicians to request an immediate exception to a payer's step-therapy requirement when specific clinical circumstances apply, such as:

• The required first-line drug is contraindicated for the patient
• The patient previously failed the required therapy (step therapy already completed)
• The step-therapy requirement would cause clinically significant harm
• The patient was stable on dupilumab under a prior plan and switching would cause harm

If you are in one of these protected states and Anthem's step-therapy requirement is causing a treatment delay, ask your physician to file a step-therapy override request under the applicable state law. The National Alliance of Mental Illness (NAMI) and the Global Healthy Living Foundation both maintain updated maps of states with step-therapy protections, though the most current legislative status should be confirmed with your state insurance commissioner's office.

Frequently Asked Questions